The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

At the recent Eudēmonia Summit, Dr. Sara Gottfried explained why understanding the root cause of chronic illness is more ...

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...